PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50322F80027Purpose of THIS requirement IS to — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79722D0178. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 25, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Aspr/Orm-Sns

Awarding office

Glaxosmithkline LLC

Recipient

Sep 25, 2023

PoP end

$7.3M

Obligated

$7.3M

Potential

325412

NAICS

Q517

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal

Contract number75A50322F80027

Also listed as36F79722D0178-75A50322F80027

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentGlaxosmithkline LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSCQ517

Parent IDIQ / IDV36F79722D0178

Place of performanceWASHINGTON DC

Pricing typeFixed Price Award Fee

Extent competedFull And Open Competition

Related solicitation75A50322Q00027

PoP startSep 26, 2022

PoP end (current)Sep 25, 2023

Obligated$7.3M

Current value$7.3M

Potential value$7.3M

THE PURPOSE OF THIS REQUIREMENT IS TO ACQUIRE AND STOCKPILE 277,632 PKGS OF RELENZA (ZANAMIVIR) ROTADISK, 5MG, NDC 00173-0681-22, OVER A 12-MONTH PERIOD. is a federal award for Aspr/Orm-Sns held by Glaxosmithkline LLC. Estimated value $7.3M ($7.3M obligated). Current period of performance ends Sep 25, 2023. Last award drew 1 bidder. Place of performance: WASHINGTON DC. Related solicitation 75A50322Q00027.

THE PURPOSE OF THIS REQUIREMENT IS TO ACQUIRE AND STOCKPILE 277,632 PKGS OF RELENZA (ZANAMIVIR) ROTADISK, 5MG, NDC 00173-0681-22, OVER A 12-MONTH PERIOD.

Recompete timing

Public

● Past PoP end (1061 days ago)

Current PoP ended Sep 25, 2023 (1061 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50125F61019

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E

$491K

Aug 30, 2026

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50322F80027?

75A50322F80027 (Purpose of THIS requirement IS to) is a Aspr/Orm-Sns award with a potential value of $7.3M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50322F80027?

Aspr/Orm-Sns awarded 75A50322F80027 to Glaxosmithkline LLC (potential $7.3M).

Who is the incumbent on 75A50322F80027?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Sep 25, 2023.

When does Glaxosmithkline LLC’s 75A50322F80027 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 25, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Sep 29, 2023